Following an 11-month shortage, the Food and Drug Administration (FDA) has announced that Agrylin (anagrelide HCl; Shire) 0.5mg capsules are now available.

The shortage was first posted on January 6, 2016 regarding the 0.5mg strength capsules for oral administration (NDC 54092-063-01).  

Related Articles

The FDA also updated that Teva‘s generic Anagrelide HCl Oral Capsules are now available after its shortage in the following presentations: 0.5mg (NDC 00172-5240-60) and 1mg (NDC 00172-5241-60) strength capsules in 100-count bottles. 

Agrylin, a platelet-reducing agent (PDE3 inhibitor), is indicated for the treatment of thrombocythemia, secondary to myeloproliferative disorders, to reduce elevated platelet count and the risk of thrombosis and to improve symptoms.

For more information visit or